Article info
Recommendation
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
- Correspondence to Professor Xavier Mariette, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, INSERM UMR1184, Department of Rheumatology, Université Paris-Saclay, 91190 Saint-Aubin, Île-de-France, France; xavier.mariette{at}aphp.fr
Citation
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
Publication history
- Received December 15, 2020
- Revised January 11, 2021
- Accepted January 27, 2021
- First published February 5, 2021.
Online issue publication
May 12, 2021
Article Versions
- Previous version (5 February 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.